title: Preemptive living donor renal transplantation: a single-center experience.
abstract: Renal transplantation is considered preemptive if it occurs before initiation of dialysis. In our experience and in the literature, preemptive transplantation has been shown not only to reduce the costs of renal replacement therapy but also to avoid the long-term adverse effects of dialysis. Preemptive renal transplantation therefore is associated with better survival of both the allograft and the recipient. Our aim was to evaluate the outcomes of preemptive renal transplantation experience at our center. Since 1985, 1385 renal transplantations have been performed at our center. We retrospectively analyzed the 16/1385 recipients (11 male, 5 female) of overall mean age of 28.5 +/- 15 years who underwent preemptive procedures. The causes of end-stage renal failure were focal segmental glomerulosclerosis (n = 5), vesicular ureteral reflux (n = 4), Berger disease (n = 2), polycystic renal disease (n = 2), and others (n = 3). Ten patients were adults, the remaining six, children. The mean creatinine clearance and plasma creatinine levels of the recipients before renal transplantation were 13.5 +/- 8.5 mL/min and 6.7 +/- 2.4 mg/dL, respectively. All renal transplantations were performed from living related donors. The mean preoperative serum creatinine levels, mean glomerular filtration rate, and creatinine clearance rates of the donors were 0.8 +/- 0.1 mg/dL, 61.6 +/- 6.5 mL/min, and 112.5 12 mL/min, respectively. Two episodes of acute cellular rejection and one of humoral rejection occurred during a mean follow-up of 48.7 +/- 14 months (range = 25-76 months). The two patients who experienced graft losses due to humoral rejection or chronic rejection were retransplanted 2 and 48 months thereafter, respectively. At this time all patients are alive with good renal function. In conclusion, our single-center results are promising for preemptive renal transplantation as the optimal, least-expensive mode of treatment for end-stage renal disease.
authors.affiliation: Department of General Surgery, Başkent University Faculty of Medicine, Ankara, Turkey. rektorluk@baskent-ank.edu.tr
authors.forename: M
authors.initials: M
authors.lastname: Haberal
authors.forename: H
authors.initials: H
authors.lastname: Karakayali
authors.forename: S
authors.initials: S
authors.lastname: Sevmis
authors.forename: S
authors.initials: S
authors.lastname: Akbulut
authors.forename: T
authors.initials: T
authors.lastname: Colak
authors.forename: E
authors.initials: E
authors.lastname: Baskin
authors.forename: G
authors.initials: G
authors.lastname: Moray
authors.forename: A
authors.initials: A
authors.lastname: Torgay
authors.forename: G
authors.initials: G
authors.lastname: Arslan
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007674:Kidney Diseases / Q000145:classification / Q000601:surgery*; D016030:Kidney Transplantation / Q000191:economics / Q000502:physiology*; D019520:Living Donors / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000191:economics; D011183:Postoperative Complications / Q000453:epidemiology; D006435:Renal Dialysis / Q000191:economics; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D003404:Creatinine